Biotech
Merck Just Turned a $600-a-Month Injection Into a $315 Pill — and Cut Cholesterol 59%
Merck's Lipfendra (enlicitide) is the first oral PCSK9 inhibitor — a once-daily pill that cuts LDL up to 59%, matching the injectables at $315 a month.
Topic
Merck
The latest Merck news and analysis from Tech Arcade.